Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR -Mutated Non-Small Cell Lung Cancer
JNCI: Journal of the National Cancer Institute · 08.06.2023 · 115 (6) · 742-748
DOI: 10.1093/jnci/djac015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 30.01.2022. Verfasst von Xiao-Shan Wang und 30 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 242-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Foundation, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Clinical Research and Transformation Fund of Sichuan Provincial People’s Hospital.
Abstract (Originalsprache)
Background
Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)–mutated NSCLC remains unknown. The SINDAS trial (NCT02893332) evaluated first-line tyrosine kinase inhibitor (TKI) therapy for EGFR-mutated synchronous oligometastatic NSCLC and randomized to upfront RT vs no RT; we now report the prespecified interim analysis at 68% accrual.
Methods
Inclusion criteria were biopsy-proven EGFR-mutated adenocarcinoma (per amplification refractory mutation system or next generation sequencing), with synchronous (newly diagnosed, treatment naïve) oligometastatic (≤5 metastases; ≤2 lesions in any one organ) NSCLC without brain metastases. All patients received a first-generation TKI (gefitinib, erlotinib, or icotinib), and randomization was between no RT vs RT (25-40 Gy in 5 fractions depending on tumor size and location) to all metastases and the primary tumor/involved regional lymphatics. The primary endpoint (intention to treat) was PFS. Secondary endpoints included OS and toxicities. All statistical tests were 2-sided.
Results
A total of 133 patients (n = 65 TKI only, n = 68 TKI with RT) were enrolled (2016-2019). The median follow-up was 23.6 months. The respective median PFS was 12.5 months vs 20.2 months (P < .001), and the median OS was 17.4 months vs 25.5 months (P < .001) for TKI only vs TKI with RT. Treatment yielded no grade 5 events and a 6% rate of symptomatic grade 3-4 pneumonitis in the TKI with RT arm. Based on the efficacy results of this prespecified interim analysis, the ethics committee recommended premature cessation of this trial.
Conclusions
As compared with a first-line TKI alone, addition of upfront local therapy using RT statistically significantly improved PFS and OS for EGFR-mutated NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China.
- Southwest Medical University, Luzhou City, Sichuan Province, China.
- Boao Evergrande International Hospital, Qionghai, Hainan Province, China.
Förderung
- National Science and Technology Foundation
- Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
- Clinical Research and Transformation Fund of Sichuan Provincial People’s Hospital
- Sichuan Science and Technology Office
- Chengdu Science and Technology Innovation Research and Development Project
Zitieren
APA
Wang, X. S., Bai, Y. F., Verma, V., Yu, R. L., Tian, W., Ao, R., Deng, Y., Zhu, X. Q., Liu, H., Pan, H. X., Yang, L., Bai, H. S., Luo, X., Guo, Y., Zhou, M. X., Sun, Y. M., Zhang, Z. C., Li, S. M., Cheng, X., …, & Zeng, M. (2023). Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR -Mutated Non-Small Cell Lung Cancer. JNCI: Journal of the National Cancer Institute, 115(6), 742-748. https://doi.org/10.1093/jnci/djac015
Vancouver
Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR -Mutated Non-Small Cell Lung Cancer. JNCI: Journal of the National Cancer Institute. 2023;115(6):742-748. doi:10.1093/jnci/djac015
BibTeX
@article{Wang2023,
author = {Wang, Xiao-Shan and Bai, Yi-Feng and Verma, Vivek and Yu, Rui-Lian and Tian, Wei and Ao, Rui and Deng, Ying and Zhu, Xue-Qiang and Liu, Hao and Pan, Hai-Xia and Yang, Lan and Bai, Han-Song and Luo, Xing and Guo, Yan and Zhou, Ming-Xiu and Sun, Yue-Mei and Zhang, Zi-Can and Li, Si-Min and Cheng, Xue and Tan, Bang-Xian and Han, Liang-Fu and Liu, Ying-Yi and Zhang, Kai and Zeng, Fan-Xin and Jia, Lin and Hao, Xin-Bao and Wang, You-Yu and Feng, Gang and Xie, Ke and Lu, You and Zeng, Ming},
title = {Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR -Mutated Non-Small Cell Lung Cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2023},
volume = {115},
number = {6},
pages = {742--748},
doi = {10.1093/jnci/djac015}
}
EUVIMED